The ratio of pY1586 to total ALK revealed a mean decrease to 0.34 following crizotinib treatment versus 0.17 following ceritinib treatment (each normalized to the mean of their respective vehicle controls) (Fig. 4E), indicating a larger pharmacodynamic effect with ceritinib, consistent with the tumor volume data (Fig. 4A). Here, ALK is linked to neoplasm.